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ABSTRACT	
Sex	hormones	are	associated	with	the	physiology	and	pathophysiology	of	almost	all	
organs	in	body,	as	well	as	most	diseases.	Interest	in	the	associations	between	sex	
hormones	and	ocular	tissues	has	increased	in	recent	years.	Androgens	may	have	a	
positive	effect	on	dry	eye,	whereas	the	effects	of	estrogen	on	ocular	conditions	remain	
unclear.	Intracrinology,	the	local	synthesis	and	metabolism	of	hormones	which	is	
unique	to	humans,	is	of	relevance	to	the	eye	and	may	help	to	explain	why	studies	of	the	
relationship	between	estrogens	and	dry	eye	signs	and	symptoms	are	inconclusive.	
Knowledge	of	the	pathways	of	hormone	formation	and	metabolism	is	crucial	to	
understanding	the	pathogenesis	of	ocular	disease	including	dry	eye.	This	review	
examines	the	mechanisms	of	steroidal	sex	hormone	biosynthesis	and	reviews	the	
significance	of	locally	produced	sex	hormones,	with	a	focus	on	ocular	surface	tissues.	
Much	of	the	current	literature	is	based	on	animal	studies,	which	may	not	be	transferable	
to	humans	due	to	the	absence	of	intracrine	production	in	animals.	A	large	proportion	of	
the	human	studies	investigate	systemic	hormones	levels	rather	than	local	levels.	There	
is	subsequently	a	need	for	additional	studies	to	provide	a	better	understanding	of	the	
local	production	of	sex	hormones	within	the	human	eye	and	ocular	surface	and	to	
clarify	the	relationships	between	ocular	levels	of	sex	hormones	and	conditions	including	
dry	eye.		
	
KEYWORDS	intracrinology,	androgens,	estrogens,	dry	eye	disease,	MGD,	ocular	surface	
Abbreviations	are	printed	in	boldface	where	they	first	appear	with	their	definitions.	
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Literature	review:	methods	
A	review	was	conducted	to	assess	whether	the	local	synthesis	of	sex	hormones	has	
consequences	for	the	physiology	and	function	of	the	ocular	surface	and	a	subsequent	
impact	on	dry	eye	disease.	Relevant	articles	were	identified,	published	to	July	2017,	
through	searches	in	PubMed,	Scopus	and	Medline	databases	as	well	as	through	the	
reference	lists	of	identified	publications.	Searches	were	performed	for	meeting	
abstracts	for	the	American	Academy	of	Optometry	(AAO),	the	American	Academy	of	
Ophthalmology	(AAO),	the	Tear	Film,	and	Ocular	Surface	Society	(TFOS)	and	the	
Association	for	Research	in	Vision	and	Ophthalmology	(ARVO).	Patent	searches	were	
also	carried	out.	
Search	terms	included:	sex	hormones,	sex	steroids,	intracrinology,	estradiol,	estrogen,	
testosterone,	androgen	and	steroidogenesis.	Additional	search	terms	for	each	section	
include:	Section	II:	endocrinology;	III	[A]	meibomian	gland,	lacrimal	gland,	cornea	and	
conjunctiva,	receptors,	mRNA,	gene	regulation,		[B]	mass	spectrometry,	tears,	meibum,	
blood,	human,	[C]	ocular	impact,	hormone	replacement	therapy,	oral	contraception,	
estrogen	therapy,	androgen	therapy,	treatment,	topical,	dry	eye,	keratoconjunctivitis	sicca,	
MGD,	symptoms,	TBUT,	Schirmer,	function;	[B]		.	
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I. INTRODUCTION:	SEX	AND	DRY	EYE	
Epidemiology		
Approximately	3.2	million	women	and	1.68	million	men	in	the	United	States	suffer	from	
severe	dry	eye	symptoms	or	clinically	diagnosed	dry	eye,	with	millions	more	
experiencing	less	intense	symptoms.	[1,2]	Large	epidemiological	studies	have	identified	
female	sex	and	older	age	as	risk	factors	for	the	development	of	dry	eye.	[1–10]	The	risk	
of	experiencing	dry	eye	appears	to	increase	over	two	times	with	menopause.[11]		
Pathophysiology	
Dry	eye	occurs	when	the	tear	film	is	compromised,	either	by	reduced	aqueous	
production	or	increased	evaporation:	tear	quality	and	stability	is	thus	impaired.	The	
pathogenesis	of	dry	eye	is	complex	and	as	yet	not	completely	understood.	Its	aetiology	
is	multifactorial;	in	addition	to	inflammatory	processes	and	neural	feedback	
mechanisms,	there	is	also	strong	evidence	for	a	hormone‐mediated	contribution.[9,12]	
Treatment	of	dry	eye	
Medications,	such	as	anti‐inflammatory	and	anti‐biotic	agents,	can	be	used	for	treating	
processes	involved	in	dry	eye,	including	reducing	the	presence	of	inflammatory	
mediators		or	pathogens	on	the	ocular	surface.[13]	However,	many	traditional	
treatments	for	dry	eye	disease	are	only	palliative,	including	artificial	lubricants	or	
retention	plugs,	aimed	at	increasing	the	volume	of	tears	on	the	ocular	surface.	A	
treatment	directed	at	the	underlying	cause	has	the	potential	to	provide	effective	relief	to	
the	millions	of	people	worldwide	who	suffer	from	dry	eye	disease;	this	is	not	currently	
possible	due	to	the	current	uncertainty	of	the	pathophysiology	of	dry	eye.		
	Sex‐related	differences	
Sex‐related	differences	are	found	in	almost	every	cell	and	tissue	in	the	body,	thus	it	is	
rational	to	expect	that	sex‐differences	also	occur	in	ocular	tissues.	[14]		Vernal	
keratoconjunctivitis	(VKC)	is	a	well‐documented	example	of		an	ocular	surface	disease	
which	shows	significant	sex‐related	prevalence,	with	over	three	quarters	of	patients	
being	male.[15]		VKC	also	shows	a	tendency	to	resolve	around	puberty,	in	both	males	
and	females,	which	suggests	a	hormonal	effect	on	VKC.	[15]	In	addition,	the	number	of	
estrogen	and	progesterone	receptors	in	the	epithelium	and	sub	epithelium	of	the	tarsal	
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and	bulbar	conjunctiva	has	been	shown	to	increase	with	disease	duration,	which	
suggests	a	possible	relationship	between	these	hormones	and	VKC.	[16]	
This	review	examines	the	mechanisms	of	steroidal	sex	hormone	biosynthesis	and	
considers	the	implications	of	local	hormone	production	on	investigations	of	hormone	
effects	on	dry	eye.		
II. SEX	HORMONES	
Sex	hormones,	including	androgens	and	estrogens,	are	steroids	responsible	for	some	of	
the	most	profound	changes	which	occur	to	the	body.	Sex	hormones	are	associated	with	
the	physiology	and	pathophysiology	of	almost	all	organs,	as	well	as	most	diseases.		
Figure	1	shows	the	steroidogenic	pathways.		
 Sex	hormone	biosynthesis	
1. Synthesis	of	circulating	sex	hormones	
Androgens	and	estrogens	are	biologically	active	in	both	sexes	and	it	is	erroneous	to	
associate	estrogens	with	female	and	androgens	exclusively	with	male	sex.		In	men	the	
testes	provide	a	near	continuous	supply	of	androgens	and	small	amounts	of	estrogens	
through	a	male’s	lifetime.[17]	In	women	the	ovaries	secrete	estrogens,	progesterone	
and	androgens.	However	at	menopause	ovarian	secretion	of	estrogen	and	progesterone	
stops.[18]	Women	undergo	a	slow	decline	in	testosterone	with	age,	which	doesn’t	
appear	to	be	associated	with	the	final	menstrual	period.[19]		
In	adult	men,	blood	testosterone	levels	are	100‐150x	the	level	of	estradiol.[20]	In	pre‐
menopausal	adult	women,	during	the	early	follicular	phase	of	the	menstrual	cycle	
(when	estrogen	and	progesterone	levels	are	low),	circulating	testosterone	levels	are	2‐
3x	that	of	estradiol,	with	the	ratio	increasing	post‐menopause	(>5years)	to	80	times	the	
level	of	estradiol.	[21]		
2. Intracrinology:	Synthesis	of	sex	hormones	in	peripheral	tissue	
As	well	as	being	secreted	by	the	gonads	and	adrenals,	sex	hormones	are	produced		in	
peripheral	tissues	throughout	the	body	from	circulating	precursors	of	adrenal	or	
gonadal	origin.[22]		Intracrinology	was	pioneered	as	a	new	branch	of	endocrinology	by	
Ferdinand	Labrie,	in	the	late	1980’s,	describing	the	mechanisms	of	the	synthesis	of	
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active	hormones	in	peripheral	tissues	from	DHEA	and	its	sulfate	DHEA‐S	(see	FIG	1).	
During	intracrinology,	hormones	exert	their	action	within	the	same	cells	in	which	they	
are	synthesized	and	in	which	they		are	metabolized	before	being	released	into	
circulation	as	inactive	compounds.[22]	The	intracellular	inactivation	of	sex	hormones	
prior	to	release	into	extracellular	space	protects	neighbouring	tissues	from	the	action	of	
sex	hormone	thus	avoiding	possible	adverse	effects	of	their	systemic	circulation.[23]			
A	key	difference	between	endocrinology	and	intracrinology	is	that	endocrine	organs,	
such	as	the	ovaries,	disperse	synthesized	sex	hormones	via	general	circulation	to	all	
bodily	tissues.	Conversely,	intracrinology	allows	individual	tissues	to	synthesize	the	
required	amount	of	estrogens	and	androgens	without	releasing	significant	amounts	of	
biologically	active	hormones	into	circulation.[24,25]			As	the	only	animal	species	with	
adrenals	that	secrete	large	amounts	of	DHEA	and	dehydroepiandrosterone	sulfate	
(DHEA‐S),	humans	and	other	primates	are	unique	in	their	ability	to	produce	hormones	
locally.[23]	DHEA	and	DHEA‐S	are	received	by	the	local	cells	from		circulation	then	
converted	into	androstenedione	(4‐dione)	and	subsequently	into	androgens	and	
estrogens	(FIG	1)	[26]	at	levels	required	by	the	specific	cells.[24]		There	is	an	abundance	
of	DHEA	in	serum,	with	serum	levels	of	DHEA	being	about	10	times	higher	than	
testosterone	levels,	and	500	times	higher	than	estradiol	levels.[27]		
In	humans,	DHEA	levels	in	circulation	reach	maximum	levels	between	age	20‐30	years,	
decreasing	by	80%	by	the	age	of	70	in	males	and	females.[28],[29]	This	great	reduction	
in	adrenal	secretion	of	DHEA	and	DHEA‐S	results	in	a	large	fall	in	the	formation	of	
androgens	and	estrogens	in	peripheral	tissues	with	age.[30]	If	tear	producing	tissues	
are	presumed	to	produce	sex	hormones	locally	by	intracrinology,	this	drop	in	DHEA	and	
DHEA‐S	could	be	a	contributing	factor	to	the	increase	of	dry	eye	with	age.[3]	
Celec	describes	DHEA	as	a	“human	molecule”	because	levels	in	humans	are	so	much	
higher	than	in	animal	species.[31]		The	adrenals	of	rats	and	other	animals	do	not	secrete	
significant	amounts	of	DHEA	required	for	synthesis	of		sex	hormones	by	
intracrinology.[32]	Consequently	rodents,	who	secrete	sex	steroids	solely	from	the	
gonads,	are	very	different	to	humans.	Hence	as	animals	lack	the	ability	to	make	
hormones	locally,	caution	should	be	taken	when	applying	rodent/animal	models	to	
human	models.	As	a	result,	this	review	focusses	on	human	studies.		
6	
	
III. SIGNIFICANCE	OF	INTRACRINOLOGY	
Measuring	testosterone	and	DHT	concentrations	in	serum	indicates	testicular	function,	
in	men,	or	ovarian	function,	in	women,	and	does	not	include	local	intracrine	production.	
Almost	all	androgens	in	women	are	made	in	peripheral	tissues.	The	total	androgen	pool	
in	both	men	and	women	can	be	better	estimated	by	the	serum	concentrations	of	
androgen	metabolites:	androsterone	glucuronide	(ADT‐G),	3α‐diol‐G	and	3β‐diol‐G.[33]	
In	men	it	is	estimated	that	30‐50%	of	total	androgens	are	synthesized	locally	from	
inactive	adrenal	precursors.[34]	Using	the	sum	of	these	androgen	metabolites	in	blood,	
androgen	production	in	post‐menopausal	women	has	been	calculated	to	be	over	two	
thirds	of	that	of	men,	much	higher	than	previously	thought,	[35]	yet	their	serum	
testosterone	concentration	is	only	3%	that	of	men	(15ng/dL	in	women,	461ng/dL	in	
men).[20,21]	Therefore,	measuring	metabolite	levels	rather	than	levels	of	active	
androgens	provides	a	more	accurate	indication	of	the	amount	of	active	androgens	
within	peripheral	tissues.	
Estrogens	produced	by	intracrine	processes	are	also	important.	Labrie	estimates	that	
pre‐menopause,	75%	of	estrogens	are	made	in	peripheral	tissues	by	intracrinology,	
with	this	increasing	to	100%	after	menopause	(as	depicted	in	Figure	2).[22,26,33]	
Although	the	percentage	of	estrogens	being	produced	by	intracrinology	increases	post‐
menopause,	the	total	estrogen		produced	is	lower	compared	with	pre‐menopause	where	
there	are	both	endocrine	and	intracrine	sources.	To	achieve	a	better	estimation	of	the	
amount	of	estrogens	in	the	human	body	many	published	studies	measure	estrogen	
metabolites.	These	include,	but	are	not	limited	to,	hydroxylated	metabolites	such	as	2‐
hydroxyestrone,	2‐hydroxyestradiol,	16α‐hydroxyestrone	and	estriol	[36]	or	sulphated	
metabolites.[37]	
	Intracrine	synthesis	of	sex	hormones	is	vital	for	maintaining	normal	function	in	
humans.	Peripheral	tissues	require	access	to	high	circulating	levels	of	DHEA	and	to	
intracrine	enzymes,	including	aromatase,	5α‐reductase,	17β‐HSD	and	3β‐HSD,	to	enable	
biosynthesis	of	estrogens	and/or	androgens.[33,38]	All	human	tissues,	except	the	
endometrium,	possess	these	enzymes	(reviewed	by	Labrie)[24]	thus	intracrinology	
allows		circulating	levels	of	estrogens	to	remain	sub	threshold	post‐menopause.	This	
avoids	stimulation	of	the	endometrium,	whilst	allowing	tissues	to	create	their	own	
estrogens	as	needed.	
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 Sex	hormones	and	the	ocular	surface	
Human	ocular	surface	tissues,	like	other	peripheral	tissues,	are	thought	to	make	sex	
hormones	at	levels	required	by	each	tissue,	by	intracrine	processes.[22]	It	is	proposed	
that	circulating	sex	hormones	and	metabolites	are	supplied	to,	and	removed	from,	the	
ocular	surface	in	a	similar	way	to	other	nutrients:	via	diffusion	into	and	from	the	tear	
fluid,	and	blood	vessels	in	the	conjunctiva	and	other	ocular	tissues.	During	
intracrinology,	these	sex	hormones	are	used	within	the	cells	in	which	they	are	
synthesised,	with	minimal	release	of	active	hormone	out	of	the	tissue.	The	metabolites	
are	then	released	into	circulation	and	may	also	be	released	into	the	tears.	
Table 1: Summary of intracrine machinery identified in human ocular surface tissue. 
1. Steroidogenic	enzymes	in	human	ocular	surface	tissues		
The	transformation	of	adrenal	precursor	steroids,	DHEA	and	DHEA‐S,	into	androgens	or	
estrogens	relies	on	the	expression	of	steroidogenic	enzymes	in	peripheral	tissues.	[30]	
Steroid	sulfatase,	aromatase,	glucuronosyltransferase,	3β‐HSD‐∆‐5∆4‐isomerase	type	1,	
17β‐HSD	types	1	and	3,	and	5α‐reductase	types	1	and	2		are	all	required	for	the	
conversion	of	DHEA‐S	to	androgens	and	estrogens,	and	then	for	metabolism	into	their	
inactive	glucoronate	and	sulfated	forms	(FIG	1).[24]		mRNAs	for	all	of	the	above	
Intracrine	machinery	 Cornea Conjunctiva Meibomian	gland	 Lacrimal	gland
Receptor	 	 	
AR	 			+	([39],[40]) +	([39]) 		+	([39,41,42],)	 +	([39])
ER	 +	([40]) +	([43]) +	([41,44])	 +	([45])
PR	 +	([40]) +	([43]) +	([41,44])	 +	([45])
AR	mRNA	 				+	(	[46],[40]) +	([46]) +	([46])	 +	([46])
ER	mRNA	 			+	([46],[40]) 					+	([46],[43],[47]) +	([46])	 		+	([46],[47])
PR	mRNA	 			+	([46],[40]) 		+	([46],[43]) +	([46])	 +	([46])
Enzyme	mRNA	 	 	
5α‐reductase	 +	([39]) +	([39]) +	([39])	 +	([39])
steroid	sulfatase	
3β‐	HSD	(Type	1)	
17B‐HSD	(Type1+3)	
aromatase	
glucuronosyltransferase	
+	([48])	 +	([48])	 +	([48])	 +	([48])	
+	refers	to	the	finding	of	the	intracrine	machinery	in	the	ocular	tissue.	
Abbreviations:	AR:	androgen	receptors;	ER:	estrogen	receptors;	PR:	progesterone	receptors;	LG:	lacrimal	
gland;	MG:	meibomian	gland;	mRNA:	messenger	RNA,	HSD:	hydroxysteroid	dehydrogenase	
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steroidogenic	enzymes	have	been	found	in	human	lacrimal	glands	and	meibomian	
glands,	as	well	as	in	corneal	and	conjunctival	epithelial	cells[39,48]	(Table	2).	This	
suggests	that	tear	producing	tissues	are	able	to	produce	sex	hormones	by	
intracrinology.		
2. Possible	local	action	of	sex	hormones	produced	by	intracrine	processes	
Sex	steroid	receptor	mRNAs	have	been	found	in	human	ocular	surface	tissues,	as	
summarised	in	Table	1.[43,46,47,49]	If	these	mRNAs	are	translated	into	proteins	for	sex	
steroid	receptors,	ocular	surface	tissues	may	be	target	sites	for	sex	hormones	and	thus	
may	be	subject	to	the	local	action	of	these	sex	hormones.	This	supports	intracrinology	
where	sex	hormones	produced	by	intracrine	processes	exert	their	action	locally	within	
the	same	cells	in	which	they	were	formed,	before	being	metabolised	locally.	[50]	
The	presence	of	mRNA	alone	for	AR/ER/PR	does	not	prove	that	these	mRNAs	are	
translated.	However,	AR,	ER	and	PR	protein	have	been	found	in	the	epithelial	cell	nuclei	
of	human	meibomian	glands,	lacrimal	glands,	cornea,	forniceal	and	bulbar	conjunctiva	
which	implies	translation.	[39–45]		The	presence	of	androgen/	estrogen/	progesterone	
receptor	protein	suggests	these	receptors	may	facilitate	sex	hormone	influence	on	the	
function,	structure	and	pathology	of	the	tear	producing	tissues.	[39]	However,	no	
association	has	been	reported	between	the	number	of	estrogen	receptors	in	meibomian	
gland	basal	cells	and	dry	eye	symptoms,	tear	quality	(Tear	Break	Up	Time	[TBUT]),	or	
tear	volume	(Schirmer	score).[42]		
3. Gene	regulation	of	ocular	surface	tissues	by	sex	hormones	
To	establish	whether	sex	steroids	have	sex‐specific	or	antagonistic	effects,	studies	have	
examined	the	influence	of	sex	hormones	on	gene	expression	in	epithelial	cells	of	human	
meibomian	glands	and	conjunctiva,	and	mice	lacrimal	glands	and	meibomian	glands.	
Sex	hormone	effect	on	gene	expression	is	not	limited	to	sex	hormones	produced	by	
intracrine	processes,	therefore	animal	studies	are	used	to	support	the	two	published	
human	studies	discussed	in	this	section.			
Sex	appears	to	have	a	significant	influence	on	gene	expression	in	ocular	surface	tissues,	
affecting	genes	responsible	for	a	broad	range	of	processes.	[51–53]	However,	the	
influence	of	sex	on	gene	expression	seems	to	be	tissue‐specific,	with	the	majority	of	sex	
related	differences	in	gene	expression	in	the	mouse	meibomian	gland	being	different	to	
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those	in	the	mouse	lacrimal	gland.[54]		The	most	highly	expressed	genes	in	human	
meibomian	glands	were	unique	to	those	in	the	human	conjunctival	epithelia,	thus	gene	
expression	appears	to	be	tissue‐specific	in	humans	as	well	as	mice.	[52]	
Treatment	of	immortalised	human	meibomian	gland	epithelial	cells	(iHMGEC)	and	
conjunctival	epithelial	cells	(iHCEC)	in	serum‐free	medium	with	DHT	was	found	to	
influence	expression	of	approximately	3000	genes.	[53]	in	iHCEC	DHT	enhanced	
expression	of	genes	involved	in	the	development	of	the	epithelium,	wound	healing	and	
regeneration,	whilst	suppressing	genes	related	to	immune	response	and	mitotic	cell	
cycle.[53]	Androgen	treatment	in	the	meibomian	gland	increased	expression	of	genes	
for	lipogenesis	and	suppressed	genes	for	keratinisation.[53]	Some	genes	were	up/down	
regulated	in	both	tissues,	however	as	described	above,	most	gene	regulation	was	unique	
to	the	meibomian	or	conjunctival	epithelium	cells.[53]	These	findings	by	Khandelwal	et	
al	suggest	that	androgens	appear	to	be	beneficial	to	the	physiology	of	meibomian	glands	
and	conjunctiva.	
The	only	study	to	look	at	the	effect	of	both	estrogens	and	androgens	in	vitro	in	human	
ocular	surface	tissues	(sex	unknown)	is	by	Schroder	et	al.52	This	study	used	1nM	17β‐
Estradiol	and	10nM	DHT	to	modulate	gene	expression	of	meibomian	gland	dysfunction	
(MGD)	associated	markers	in	iHMGEC.[41]	iHMGEC	cultured	in	serum‐free	medium	
were	compared	to	those	cultured	in	serum‐containing	medium.	Both	estradiol	and	DHT	
increased	gene	expression	for	keratinisation	in	serum‐free	medium	and,	interestingly,	
DHT	also	down	regulated	gene	expression	of	lipid	synthesis	enzymes.[41]	These	
findings	contrast	with	the	positive	effects	of	androgens	on	iHMGEC,	found	by	
Khandelwal58	and	in	mice	studies.[55–57]	Schroder	et	al52	also	found	estradiol	to	
increase	genes	for	proliferation	of	iHMGEC,	which	disagrees	with	the	findings	of	a	
preliminary	study	which	found	estradiol	to	decrease	proliferation.	[58]	The	
contradictory	results	could	be	explained	bydifferences	in	methodology	between	
research	groups,	including,	but	not	limited	to,	the	use	of	serum	containing	medium,	
hormone	concentrations	studied	and	the	use	of	immortalized	cell	lines.	As	with	topical	
or	systemic	treatment	in	vivo,	the	effect	of	estrogen	on	human	ocular	tissues	remains	
unclear.	The	effect	of	sex	hormones	on	gene	expression	in	human	ocular	tissues	is	
complex.	With	only	two	published	studies	investigating	these	effects	it	is	not	yet	
possible	to	form	firm	conclusions.	
10	
	
Testosterone	significantly	altered	the	expression	of	thousands	of	genes	in	the	lacrimal	
and	meibomian	glands	of		mice.[57]	Interestingly,	androgens	impacted	expression	of	
genes	involved	in	lipid	metabolism	and	inhibition	of	keratinization	in	the	mouse	
meibomian	gland.[57]	This	agrees	with	the	study	of	iHMGEC	by	Khandelwal	et	al.[53]	
Many	of	the	biological	and	functional	effects	of	androgens	were	the	same	in	both	males	
and	females.	[57,59]Estrogen	and	progesterone	also	influenced	expression	of	numerous	
genes	in	the	mouse	lacrimal	gland	[59]	and	meibomian	gland.	[60]	However,	their	
effects	tended	to	be	unique	to	those	of	androgens	and	the	number	of	common	genes	was	
limited:	estradiol,	progesterone	or	a	combination	of	both	sex	steroids	significantly	
influenced	less	than	7%	of	genes	controlled	by	androgens.[57]		Although	sex	hormones	
impacted	expression	of	thousands	of	genes	in	the	lacrimal	and	meibomian	glands	of	
mice,	testosterone	and	estrogen	appear	to	have	different	effects.	Testosterone	appears	
to	promote	meibomian	gland	function,	which	agrees	with	studies	of	androgen	treatment	
(see	review	by	Truong	et	al).[61]	
The	absence	of	estrogen,	as	a	result	of	aromatase	elimination,	was	associated	with	
up/downregulation	of	thousands	of	genes	in	the	mouse	meibomian	gland	and	lacrimal	
gland.[62,63]	More	than	90%	of	these	aromatase‐linked	genes	were	sex‐specific	which	
could	explain	the	sex	related	differences	of	the	mouse	meibomian	and	lacrimal	
glands.[62,63]	There	was	no	effect	on	tear	volume	in	females,	however	a	significant	
increase	in	tear	volume	in	male	mice	was	observed[62,63]	which	suggests	sex	specific	
influences.	Thus	it	appears	that	estrogen	and	aromatase	play	an	important	part	in	gene	
regulation	in	mice	meibomian	and	lacrimal	glands.	[62,63]	However	this	effect	appears	
to	be	sex	specific.	
In	summary,	there	are	very	few	published	human	studies	of	the	effect	sex	hormones	
have	on	gene	regulation	in	tear	producing	tissues.	Mice	studies	suggest	testosterone	and	
estradiol	influence	expression	of	thousands	of	genes	in	the	lacrimal	gland	and	
meibomian	glands	and	that	estradiol	has	contrasting	effects	to	testosterone’s	
stimulatory	effect	of	meibomian	glands.	To	understand	the	true	nature	of	the	role	of	sex	
hormones	on	human	ocular	surface	tissues,	further	studies	are	required.	
 Measurement	of	sex	hormone	levels	at	the	ocular	surface	
Many	studies	examining	hormones	are	performed	using	animals;	whilst	these	have	their	
logistical	benefits,	including	having	larger	sample	sizes	available	and	ability	to	control	
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environmental	conditions,	the	outcomes	may	not	be	generalizable	to	humans.		Lower	
animal	species,	such	as	rats	and	rabbits,	are	different	to	humans	since	they	lack	
intracrine	synthesis	of	hormones.	[23]	There	are	many	other	variables	which	influence	
the	effects	of	hormones,	including	species,	sex,	age,	experimental	procedure	and	strain	
of	hormone	used.	[64]		
One	difficulty	of	investigating	local	sex	hormones	in	ocular	tissues	is	the	requirement	
for	human	tissue,	which	is	not	feasible	in	large	scale	studies.	There	are	studies	which	
use	human	ocular	tissue	following	surgical	removal,	but	these	are	rare	and	small	
scale.[46]	Another	option	is	to	measure	sex	hormones	in	samples	such	as	tears,	meibum	
or	through	conjunctival	impression	cytology,	which	(although	this	approach	may	have	
other	limitations)	may	be	harvested	non‐surgically.		
Sex	hormone	metabolites	may	enter	the	tear‐film	as	a	constituent	of	lacrimal	gland	
secretions	or	within	meibum,	as	a	possible	result	of	the	holocrine	nature	of	meibomian	
glands.	[65,66]	This	speculation	is	supported	by	the	finding	of	17β‐Estradiol	and	
progesterone	in	human	tears	(using	immunoassay	kits,	in	a	preliminary	study)	at	
concentrations	which	correlated	significantly	with	serum	levels.	[67]	
Due	to	low	concentrations	of	hormones	and	the	small	sample	volumes	available	from	
collection	of	tears,	meibum	or	impression	cytology,	highly	sensitive,	reliable	and	
repeatable	methods	are	required.	Liquid	chromatography	with	tandem	mass	
spectrometry	(LC‐MS/MS)	is	one	such	method	and	studies	utilizing	and	developing	
these	methods	have	begun	to	be	published,[68]	setting	the	standard	for	future	studies.	
They	have	the	advantage	of	improved	reproducibility,	accuracy	and	sensitivity	in	
comparison	to	immunoassays.[69–71]	To	our	knowledge,	mass	spectrometry	methods	
to	measure	sex	hormones	in	human	tears	or	meibum	have	not	been	published	to	date.	A	
preliminary	study	managed	to	successfully	detect	pregnenolone,	progesterone,	DHEA,	
androstenedione	and	testosterone,	as	well	as	corticosteroid	metabolites,	in	human	tears	
using	LC‐MS/MS.[72]	LC‐MS	and	Gas	chromatography	–MS(GC‐MS)	methods	were	
developed		to	detect		9	steroids	(testosterone,	androstenedione,	cortisol,	DHEA‐S,	DHEA,	
cortisone,	β‐estradiol,	progesterone	and	androst‐5‐ene‐3,17‐diol)	and	serotonin	in	
human	tears,		however	levels	were	too	low	to	reach	the	required	sensitivity.[73]	New	
instrumentation,	with	increased	sensitivity,	provides	the	possibility	for	future	
successful	mass	spectrometry	measurement	of	sex	hormones	in	human	tears.	
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 Sex	hormone	treatment	and	dry	eye.	
Due	to	the	difficulties	of	measuring	local	levels	of	sex	hormones,	as	discussed	in	section	
III	B,	the	relationship	between	intracrine	sex	hormones	and	clinical	signs	or	symptoms	
has	not	previously	been	investigated.	Truong	et	al	examined	evidence	for	the	role	of	
systemic	sex	hormones	in	the	aetiology	of	dry	eye	and	the	effect	of	systemic	sex	
hormones	on	ocular	function.[61]		They	concluded	that	androgens	may	have	a	beneficial	
impact	on	the	lacrimal	glands	and	meibomian	glands,	and	that	androgen	deficiency	is	a	
contributing	factor	to	dry	eye	aetiology.	They	suggested	that	the	impact	of	estrogen	is	
more	uncertain,	with	studies	finding	contradictory	effects	of	exogenous	estrogen	on	
ocular	structures,	shown	by	the	unresolved	relationship	between	HRT	and	dry	eye	signs	
and	symptoms.[61]		
It	is	important	to	note	that	although	studies	thus	far	have	looked	at	associations	
between	serum	sex	hormones	and	dry	eye,	serum	sex	hormones	represent	only	a	small	
portion	of	sex	hormones	made	in	the	body,	since	all	estrogens	and	most	androgens	are	
produced	and	metabolized	locally	in	peripheral	tissues	post‐menopause.[22,26,30]	
Topical	treatment	with	sex	hormones	may	be	a	viable	route	of	administration	for	local	
treatment	of	dry	eye.	Studies	have	used	two	different	routes	of	topical	administration:	
cream	applied	to	the	eyelids	or	eye	drops,	summarized	in	Table	2.	
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Table 2: Summary of the effects of topical androgens and estrogens on symptoms and signs of dry eye. 
Topical treatment was in the form of eye drops or cream applied to the eyelids.  
Author  No subjects Treatment Dosage Duration Placebo  Effect on Dry eye
Androgens  	
WO Patent No 1994004155 A1, 1994 
[74] 
F=1  1.5% DHEA drops / 3 weeks N  Improved symptoms, But and lipid layer, reduced 
Schirmer’s 
Worda et al 2001* [75] M=1  3% Testos cream t.i.d. 3 months N  Improved symptoms and lipid layer, restored tear film 
Connor, et al 2001 [Conference][76]  F=1, M=9 1% DHEA drops q.i.d. 2 weeks Y  Improved symptoms, Schirmer’s and TBUT
Connor 2002 [Conference] [77] F=15, M=5 2.5% Testos cream b.i.d. 3 weeks Y  Improved symptoms and Schirmer’s
Connor , et al 2002[Conference] [78]  F=9, M=11 1% Testos, 
1% DHEA drops 
q.i.d. 2 weeks Y  DHEA improved BUT & Schirmer’s
Testos decreased Schirmer’s 
US Patent No 6659985 B2, 2003[79]  F=4, M=1 2.5% DHEA cream t.i.d. 2 weeks N  Improved symptoms & CL WT.  Improved  Schirmer’s 
and TBUT in male subject only  
F=2  2.5% Testos cream b.i.d. 2 weeks N  Improved symptoms , CL WT, Schirmer’s and BUT  
Connor 2003 [Conference][80] F=25, M=3 3% Testos cream b.i.d. 2 weeks Y  Improved symptoms and Schirmer’s
Schiffman 2006[Conference] [81]  179  0.01%, 0.03%, 
0.1% Testos 
/ 6 months Y  Improved MG secretions
Connor 2007[Conference] [82]   F=40, M=10 5% Testos, 
20% Prog cream 
b.i.d. / N  Improved symptoms and TBUT
Connor 2012[Conference][83] F=30  5% Testos cream b.i.d. 1 month N  Improved TBUT
Estrogens  	 	
Lubkin 1992[Conference][84] F=14  E2 drops. 
unknown%  
q.i.d. 2 months Other eye Improved symptoms
US Patent No 6096733, 1998 [85]  F=45  0.1%, 0.25% E2 
drops 
q.i.d. 90 days Y  Improved symptoms and TBUT
F  0.05% E2 drops t.i.d. 10 days Other eye Maturation conjunctival epithelium 
Akramanian et al * 1997 & 1998 [86,87]  F=20  3% E2 ointment / 1 week Y  Improved symptoms, Schirmer’s and TBUT
Sator et al* 1998[88] F=84  0.025% E2 drops q.i.d. 4 months Y  Improved symptoms and Schirmer’s
Abbreviations: *indicates published studies, [Conference]: conference proceedings, F: Female, M: Male, Testos : testosterone, Prog: progesterone, E2: Estradiol, /: unknown, b.i.d: twice 
daily, t.i.d. three times daily, q.i.d. four times daily, Y: yes, N: no,  CL WT: contact lens wearing time, TBUT; tear break up time, MG: meibomian gland. 
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In	summary,		eye	drops	and	cream	applied	to	the	eyelids,	supplemented	with	
testosterone	or	DHEA	have	a	beneficial	effect	on	symptoms,	tear	stability	and	
quantity.[75,77,80,83],[74,78]	However,	evidence	is	weak	with	an	absence	of	placebo	
controlled	published	studies	which		are	required	to	improve	our	understanding	of	the	
possible	application	of	topical	androgens	for	clinical	treatment	of	dry	eye.		
There	are	a	very	limited	number	of	studies	researching	the	effect	of	estradiol	therapy	on	
dry	eye,	including	only	two	published	controlled	studies,	one	of	which	has	many	
possible	confounding	factors.[88]		Evidence	seems	to	suggest	that	topical	estradiol	may	
be	beneficial	for	the	treatment	of	dry	eye.	This	is	in	agreement	with	studies	which	found	
systemic	estrogen	treatment	to	improve	dry	eye,[87–93]		but	disagrees	with	studies	
which	found	systemic	estrogen	therapy	to	exacerbate	dry	eye.[94–96]	Although	
systemic	estrogen	therapy	has	conflicting	results,	the	limited	results	from	studies	of	
topical	estradiol	therapy	(including	preliminary	studies)	suggest	a	positive	effect	of	
topical	treatment,	which	may	be	more	associated		with	local	synthesis	of	sex	
hormones.[24]		
Topical	estrogen	and	androgen	therapy	appears	to	have	a	positive	effect	on	signs	and	
symptoms	of	dry	eye;	however	published	evidence	is	weak	with	the	majority	of	studies	
being	preliminary.		
IV. SUMMARY	
This	review	aimed	to	provide	a	comprehensive	discussion	focussed	on	the	impact	of	
local	sex	hormone	synthesis	on	dry	eye.	It	was	necessary	to	discuss	the	wider	topic	of	
intracrinology	before	focussing	on	ocular	structures.		Despite	the	increase	in	knowledge	
of	local	hormone	synthesis,	much	of	the	recent	literature	focusses	on	the	effects	of	
circulating,	rather	than	local,	sex	hormones	on	signs	or	symptoms	of	dry	eye.	This	is	
likely	due	to	the	relative	ease	of	systemic	measurement	in	comparison	to	local.		
Much	research	regarding	sex	hormones	and	the	ocular	surface	has	been	performed	on	
rats	and	mice	to	show	the	presence	of	sex	hormone	mRNA	in,	ocular	structures;	the	
meibomian	and	lacrimal	glands	have	been	of	particular	interest	in	published	research	to	
date,	likely	due	to	their	role	in	tear	formation.	Labrie	describes	intracrinology	as	“the	
formation	of	active	hormones	that	exert	their	action	in	the	same	cells	where	synthesis	
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took	place	without	release	into	the	pericellular	compartment.”[22,23]	The	presence	of	
steroidogenic	enzymes	in	the	ocular	surface	tissues	suggests	that	human	ocular	surface	
tissues	are	capable	of	local	formation	as	well	as	inactivation	of	sex	steroids.	The	
presence	of	AR,	ER	and/or	PR	mRNA	and	protein	suggests	that	these	ocular	tissues	are	
target	sites	for	sex	hormones	and	that	once	synthesized,	the	locally	produced	sex	
steroids	may	exert	their	action	within	the	same	tissues.	This	is	supported	by	human	and	
mice	studies	which	have	demonstrated	that	androgens	and	estrogens	regulate	
numerous	genes	in	the	meibomian	gland,	lacrimal	gland	and	conjunctiva.		
The	important	physiological	role	of	estrogens	and	androgens	in	the	function	and	
structure	of	ocular	tissues	calls	for	an	improved	understanding	of	intracrine	hormone	
synthesis	and	their	metabolism.	Measurement	of		local	sex	hormone	levels	has	its	
challenges,	including	the	procurement	of	human	ocular	surface	tissue.	Measuring	levels	
of	sex	hormones	and	metabolites	in	tears	or	meibum	thus	provides	an	estimateof	ocular	
surface	tissue	levels,	without	the	need	for	tissue	excision.	Technological	advances,	
including	in	LC‐MS	and	GC‐MS,	will	provide	the	sensitivity	required	to	measure	the	low	
levels	of	sex	hormones	and	their	metabolites	which	are	present	in	human	tears	and	
meibum.	
Developments	in	technology	not	only	allow	our	understanding	of	how	sex	hormones	
influence	the	ultrastructure	of	ocular	tissues,	but	also	uncover	the	presence	of	the	
biological	machinery	needed	for	intracrine	hormone	synthesis.	Thus	it	is	anticipated	
that	with	further	technological	developments,	rapid	progress	will	be	made	in	
understanding	how	sex	hormones	affect	ocular	tissues	and	contribute	to	the	
development	of	dry	eye.	Clarification	of	the	action	of	sex	hormones	on	ocular	surface	
tissues	and	their	contribution	to	dry	eye	is	essential	for	the	development	of	suitable	
hormone	based	treatments	for	dry	eye.	
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FIG	1:	Schematic	representation	of	human	endocrine	(adrenal)	and	intracrine	
steroidogenic	pathways.	Endocrine	processes	allow	cholesterol	to	be	converted	
into	progestagens	then	androgens,	which	are	then	transformed	into	estrogens.	
DHEA	and	DHEAS	are	secreted	by	the	adrenals	and	are	used	for	steroidogenesis	
in	peripheral	intracrine	tissues.	Corticosteroids	are	also	included	as	they	are	
formed	from	the	same	precursors	(progesterone	and	17α‐hydroxyprogesterone).	
Corticosteroids	include	mineralocorticoids	(primary	being	aldosterone)	and	
glucocorticoids	(primary	being	cortisol).Italic	boxes	represent	enzymes	involved.	
Adapted	from	Labrie	2007.[28]	
Abbreviations:	DHEA:	dehydroepiandrosterone,	DHEAS:	
dehydroepiandrosterone‐sulphate,	DHT:	dihydrotestosterone	
	
FIG	2:	Schematic	representation	of	ovarian	and	adrenal	sources	of	sex	steroids	in	
premenopausal	women.	Humans	have	adrenal	glands	which	secrete	large	
quantities	of	the	precursor	DHEA	which	is	converted	into	progestogens,	
androgens	and	estrogens	in	peripheral	tissues.	After	menopause	ovarian	estradiol	
secretion	ceases,	thus	100%	of	sex	steroids	are	then	made	locally	in	tissues	by	
intracrine	pathways.	LH	stimulates	the	secretion	of	sex	hormones	from	the	
gonads	and	ACTH	modulates	adrenal	secretion	of	DHEA.		
Adapted	from	Labrie	2003.	[30]	
Abbreviations:	LH:	Luteinising	hormone,	ACTH:	adrenocorticotropin,	DHEA:	
dehydroepiandrosterone.	
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